Aveo's Tivozanib Lives to Fight Another Day With EU And Russian Filings
This article was originally published in Scrip
Executive Summary
Aveo Pharma's targeted anticancer, tivozanib, is a few steps closer to the market after two of its licensees, EUSA Pharma and Pharmstandard Group, filed the drug for approval in advanced renal cell cancer in the EU and Russia respectively.